PharmaEssentia

6446.TW

17.63 USD

-0.57

-3.13%

Overview

Last close

17.63 usd

Market cap

6.01B usd

52 week high

23.57 usd

52 week low

8.76 usd

Target price

21.1 usd

Valuation

P/E

49.4042

Forward P/E

N/A

Price/Sales

15.7773

Price/Book Value

7.2424

Enterprise Value

6.11B usd

EV/Revenue

14.7908

EV/EBITDA

50.5371

Key financials

Revenue TTM

413.17M usd

Gross Profit TTM

364.24M usd

EBITDA TTM

117.54M usd

Earnings per Share

0.36 usd

Dividend

0.03 usd

Total assets

867.04M usd

Net debt

-583.77M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.